This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weltermann, A. Articles by Kyrle, P. A. Search for Related Content PubMed PubMed Citation Articles by Weltermann, A. Articles by Kyrle, P. A. Pubmed/NCBI databases Substance via MeSH Related Collections Growth factors/cytokines Coagulation and fibronolysis Platelets

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1757-1760.)
© 1999 American Heart Association, Inc.

Thrombosis

Large Amounts of Vascular Endothelial Growth Factor at the Site of Hemostatic Plug Formation In Vivo

Ansgar Weltermann; Michael Wolzt; Kai Petersmann; Christine Czerni; Ursula Graselli; Klaus Lechner; Paul A. Kyrle

From the Department of Medicine I, Division of Hematology and Hemostaseology (A.W., K.P., C.C., K.L., P.A.K.) and the Department of Clinical Pharmacology (M.W., U.G.), Vienna University Hospital, Vienna, Austria.

Correspondence to Dr Paul A. Kyrle, Allgemeines Krankenhaus Wien, Klinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseologie, Währinger Gürtel 18-20, A-1090 Wien, Austria. E-mail Paul.Kyrle{at}akh-wien.ac.at

Abstract—Vascular endothelial growth factor (VEGF) is important for the proliferation, differentiation, and survival of microvascular endothelial cells. It is a potent angiogenic factor and a specific endothelial cell mitogen that increases fenestration and extravasation of plasma macromolecules. Recently, large quantities of VEGF were detected in human megakaryocytes. Incubation of human platelets with thrombin in vitro resulted in the release of large amounts of VEGF. To investigate whether VEGF is released from platelets during coagulation activation in vivo, we measured in human subjects VEGF at the site of plug formation, ie, in blood emerging from a standardized injury made to determine bleeding time (shed blood). VEGF was also determined in the same volunteers after treatment with the specific thrombin inhibitor recombinant hirudin (r-hirudin). In a double-blind, randomized, crossover study, 17 healthy male volunteers (aged 20 to 35 years) were investigated. VEGF concentrations were measured in venous blood and in shed blood by the use of an immunoassay 10 minutes after intravenous administration of r-hirudin (0.35 mg/kg of body weight) or physiological saline. Prothrombin fragment f1.2 (f1.2) and ß-thromboglobulin (ß-TG) were determined as indicators of coagulation and platelet activation, respectively. Concentrations of VEGF, f1.2, and ß-TG in shed blood 4 minutes after injury were significantly higher than in venous blood (VEGF, 55.8±9.2 versus <20 pg/mL, P<0.001; f1.2, 71.3±10.4 versus 0.78±0.03 nmol/L, P<0.001; ß-TG, 2290±170 versus 53.2±14.0 ng/mL, P<0.001). Administration of r-hirudin caused a >50% inhibition of the ß-TG and f1.2 levels in shed blood. In a similar manner, much lower amounts of VEGF were detectable at the site of plug formation after r-hirudin treatment (69.0±9.5 versus 37.8±2.6 pg/mL per minute; P=0.0015). Our data indicate that substantial quantities of VEGF are released from platelets during the interaction with the injured vessel wall in vivo. This finding may be relevant with respect to wound healing and tissue repair, tumor vascularization, or arterial thrombus formation.

Key Words: vascular endothelial growth factor • coagulation activation • prothrombin fragment 1.2 • ß-thromboglobulin • recombinant hirudin

This article has been cited by other articles:

				A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann Systemic blood coagulation activation in acute coronary syndromes Blood, February 26, 2009; 113(9): 2070 - 2078. [Abstract] [Full Text] [PDF]

				H. M.W. Verheul, M. P.J. Lolkema, D. Z. Qian, Y. H.A. Hilkes, E. Liapi, J.-W. N. Akkerman, R. Pili, and E. E. Voest Platelets Take Up the Monoclonal Antibody Bevacizumab Clin. Cancer Res., September 15, 2007; 13(18): 5341 - 5347. [Abstract] [Full Text] [PDF]

				K. Kobayashi, Y. Nishimura, T. Shimada, S. Yoshimura, Y. Funada, M. Satouchi, and M. Yokoyama Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome Chest, March 1, 2006; 129(3): 632 - 637. [Abstract] [Full Text] [PDF]

				E. Hormbrey, C. Han, A. Roberts, D. A. McGrouther, and A. L. Harris The Relationship of Human Wound Vascular Endothelial Growth Factor (VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis Clin. Cancer Res., October 1, 2003; 9(12): 4332 - 4339. [Abstract] [Full Text] [PDF]

				C. M. Kahler, J. Wechselberger, C. Molnar, C. Prior, R. Schulz, W. Seeger, and F. Grimminger Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe night time hypoxia Am. J. Respir. Crit. Care Med., January 1, 2003; 167(1): 92 - 93. [Full Text]

				B.C. Kuenen, M. Levi, J.C.M. Meijers, A.K. Kakkar, V.W.M. van Hinsbergh, P.J. Kostense, H.M. Pinedo, and K. Hoekman Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1500 - 1505. [Abstract] [Full Text] [PDF]

				I. Zachary, A. Mathur, S. Yla-Herttuala, and J. Martin Vascular Protection : A Novel Nonangiogenic Cardiovascular Role for Vascular Endothelial Growth Factor Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1512 - 1520. [Abstract] [Full Text] [PDF]